{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:12:36Z","timestamp":1790539956786,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.beha.2017.09.006","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T10:33:05Z","timestamp":1506076385000},"page":"312-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?"],"prefix":"10.1016","volume":"30","author":[{"given":"Richard M.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2017.09.006_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.09.006_bib2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/asheducation-2016.1.356","article-title":"MRD in AML: does it already guide therapy decision-making?","volume":"2016","author":"Ossenkoppele","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2017.09.006_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.09.006_bib4","first-page":"1911","article-title":"Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.09.006_bib5","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"FLT3: ITDoes matter in leukemia","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.09.006_bib6","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Frohling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib7","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.beha.2017.09.006_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040620714532123","article-title":"The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond","volume":"5","author":"Wander","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.beha.2017.09.006_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib10","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.09.006_bib11","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A\u00a0randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.09.006_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7016","article-title":"Effect of cytarabine\/anthracycline\/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML","volume":"35","author":"Stone","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.09.006_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib16","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B, Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2017.09.006_bib17","article-title":"Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation\/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (Alliance)","volume":"124","author":"Marcucci","year":"2014","journal-title":"Blood (ASH Annu Meet"},{"key":"10.1016\/j.beha.2017.09.006_bib18","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol cancer Ther"},{"key":"10.1016\/j.beha.2017.09.006_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7000","article-title":"Final results of a phase III randomize trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML","volume":"34","author":"Lancet","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2017.09.006_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance","volume":"19","author":"Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2017.09.006_bib21","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2017.09.006_bib22","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A\u00a0phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib23","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2017.09.006_bib24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2017.09.006_bib25","first-page":"171","article-title":"IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives","volume":"7","author":"Mondesir","year":"2016","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.beha.2017.09.006_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1070.1070","article-title":"Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1","volume":"128","author":"DiNardo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2017.09.006_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2017.09.006_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.beha.2017.09.006_bib30","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.beha.2017.09.006_bib31","article-title":"Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged \u226565 years with acute myeloid leukemia","volume":"128","author":"Wei","year":"2016","journal-title":"Blood (ASH Annu Meet"},{"key":"10.1016\/j.beha.2017.09.006_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7009","article-title":"Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients \u2265 65 years ineligible for standard induction therapy","volume":"34","author":"Pollyea","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692617300348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T03:40:40Z","timestamp":1602992440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692617300348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1521692617300348"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2017.09.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2017.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}